MICVO Monotherapy Efficacy - MICVO monotherapy demonstrated a validated efficacy signal in 2L+ R/M HNSCC, with a 46% confirmed ORR and a 92% DCR (n=13, 5.4 mg/kg)[4] - In the Phase 1 monotherapy dose expansion study at 5.4 mg/kg, Arm 1 (post-PD1/post-Platinum) showed a 60% confirmed ORR (N=5)[32] - Arm 2 (post-PD1/post-EGFRi) in the monotherapy study showed a 25% confirmed ORR (N=4), exceeding the PI benchmark of 20%+[32] - MICVO monotherapy at 5.4 mg/kg demonstrated clear activity with deep responses and exceptional disease control[35] MICVO + KEYTRUDA® Combination Efficacy - MICVO combined with KEYTRUDA® showed a promising emerging efficacy profile in 1L/2L+ R/M HNSCC, with a 71% confirmed ORR and 100% DCR (n=7, 3.6 mg/kg & 4.4 mg/kg)[4] MICVO Safety and Tolerability - MICVO at 5.4 mg/kg in R/M HNSCC showed no Grade 4 or Grade 5 ADC payload TRAEs of interest[40] - Initial data supports a lack of overlapping toxicities observed between MICVO and KEYTRUDA®[52] Market and Clinical Development - FDA aligned on a 2L+ monotherapy pivotal trial design for MICVO[4] - The US R/M HNSCC market is large, growing, and relatively uncrowded, making it ripe for innovation[17] - Projected 2029 US market data shows a significant number of drug-treatable patients, with ~31K in 1L, ~21K in 2L, and ~8K in 3L[18]

Lasofoxifene (Metastatic Breast Cancer) - The global metastatic ER+/HER2- breast cancer market is expected to grow from approximately $10.9 billion in 2025 to roughly $15.9 billion by 2029[23] - Lasofoxifene, combined with abemaciclib, demonstrated a potential best-in-class median Progression-Free Survival (PFS) of 13 months in a heavily pre-treated mESR1 population in the Phase 2 ELAINE-2 trial[26, 27, 50] - In the ELAINE-1 Phase 2 study, lasofoxifene delivered a median PFS of 24.2 weeks compared to 16.2 weeks with fulvestrant in ESR1-mutant breast cancer[48] - Approximately 70% of all breast cancers are ER+/HER2- subtype[23, 32] - Lasofoxifene reduced new onset breast cancer by 83% in a large prevention trial[30] - The ELAINE-3 registrational Phase 3 trial is ongoing, with topline results expected in mid-2027 and over 50% enrollment[16, 17, 57, 138, 139] - Assuming approximately 10% market penetration, lasofoxifene has a peak market sale potential of over $1 billion in the US market[81] ATH-1105 (ALS) - Approximately 225,000 people globally are affected by ALS, with roughly 33,000 cases in the US[98] - ATH-1105 is a CNS-penetrant positive modulator of HGF as a potential treatment for ALS[103] - A Phase 2 POC study in ALS is planned to start in the first half of 2026, with topline results expected in 2027[18, 19, 140, 141] Financial - A PIPE financing of up to $236 million, including $90 million upfront, provides cash runway through data readout and into 2028[137]

Financial Performance - Total sales reached $3.1 billion, reflecting a 7.3% increase[10] - Same-restaurant sales grew by 4.3%[10] - Adjusted EBITDA amounted to $466 million[10] - Adjusted diluted net earnings per share from continuing operations were $2.08[10] Margin Analysis - Food and beverage expenses accounted for 31.1% of sales, a decrease of 90 basis points compared to the prior year[13] - Restaurant labor expenses represented 32.2% of sales, a decrease of 10 basis points compared to the prior year[13] - Restaurant expenses accounted for 16.4% of sales, a decrease of 10 basis points compared to the prior year[13] - Marketing expenses accounted for 1.6% of sales, an increase of 10 basis points compared to the prior year[13] Fiscal Year 2026 Outlook - The company projects total sales growth of 8.5% to 9.3%, which includes approximately 2% total sales growth for the extra week[19, 20] - Same-restaurant sales growth is expected to be between 3.5% and 4.3%[19] - Adjusted diluted net earnings per share are projected to be $10.50 to $10.70[19]

1 Investment Highlights Worthington Steel Investor Presentation | December 2025 Safe Harbor Statement Selected statements contained in this release constitute "forward-looking statements," as that term is used in the Private Securities Litigation Reform Act of 1995 (the "Act"). The Company wishes to take advantage of the safe harbor provisions included in the Act. Forward-looking statements reflect the Company's current expectations, estimates or projections concerning future results or events. These statem ...

Summary of Conference Call Company and Industry - The conference call pertains to **Nordea**, a financial services group operating in the Nordic region, focusing on macroeconomic trends, interest rates, and financial performance metrics. Core Points and Arguments 1. **Macro Trends**: - Interest rates are expected to decrease by approximately **12 basis points** quarter on quarter in Q4, following rate cuts in Q3. The average decrease in three-month interbank offered rates was **19 basis points** in Sweden and **8 basis points** in Norway, while Denmark and Finland saw increases of **2 to 3 basis points** [2][3] - The USD-denominated MSCI World Index increased by **4.9%** quarter on quarter, and the OMX40 Nordic Index rose by **3.8%** [2] 2. **Net Interest Income (NII)**: - NII for Q3 was reported at **EUR 1.775 billion**, with expectations for Q4 to be lower due to a decrease in average Nordic policy rates [3][4] - The margin-driven NII saw a reduction of nearly **EUR 90 million** in Q3, with a projected contribution of around **EUR 10 million** from deposit hedges in Q4 [4][5] 3. **Net Fee and Commission Income (NCI)**: - NCI for Q3 was **EUR 811 million**, with non-recurring gains of **EUR 10 million** not expected to repeat, leading to a relevant starting point of **EUR 800 million** for Q4 [6] - The average quarterly run rate for brokerage and advisory services was around **EUR 50 million** [7] 4. **Net Insurance Results**: - Q3 net insurance results were **EUR 66 million**, benefiting from movements in medium to long-term interest rates [9] 5. **Loan Losses**: - Historically, loan losses in Q4 tend to be higher, with expectations around **10 basis points** based on long-term averages. Significant portions of management judgment buffers have already been released earlier in the year [10][11] 6. **Capital and Dividends**: - The CET1 ratio was **15.9%** at the end of Q3, with a requirement of **13.6%**. A new buyback program of **EUR 500 million** was launched, expected to reduce the CET1 ratio by **30 basis points** [12][15] - The dividend policy aims for a payout of **60%-70%** of annual profits, with a stable to growing dividend per share ambition [12][13] Other Important Content - The impact of foreign exchange (FX) movements was noted, with SEK and NOK showing minor tailwinds for euro-denominated income in Q4 [3] - The conference call emphasized the importance of tracking FX movements, particularly for the P&L statement [3] - The company plans to book a fee for interest-free deposits under regulatory fees starting Q4, with a limited impact of mid-single-digit million euros [10] - The silent period for further inquiries begins on **7 January**, with the Q4 report scheduled for release on **29 January** [1][16]

Financial Performance - Enerpac Tool Group's Q1 FY26 net sales were $144 million, a decrease of 0.7% compared to $145 million in Q1 FY25[8] - Organic sales decreased by 2.4% overall[8] - Adjusted EBITDA was $32.4 million, a 5.7% decrease compared to $34.3 million in Q1 FY25[13] - Adjusted EPS was $0.36, a 10% decrease compared to $0.40 in Q1 FY25[13] - Gross margin was 50.7%, a decrease of 70 basis points year-over-year[13] - Adjusted SG&A was 29.8% of sales, an increase of 80 basis points year-over-year[13] Segment Performance - IT&S product sales grew organically by 4%[6,8] - IT&S service sales decreased organically by 26.3%[8] - Cortland Biomedical sales grew organically by 27.3%[8] Regional Performance (IT&S) - Americas region experienced 5% organic growth[9] - EMEA region experienced a 10% organic decline[9] - APAC region experienced an 8% organic decline[9] FY26 Guidance - Net sales are projected to be between $635 million and $655 million, with organic growth of approximately 1-4%[22] - Adjusted EBITDA is expected to be between $158 million and $168 million[23] - Adjusted EPS is projected to be between $1.85 and $2.00[23]

HHH to Acquire Vantage Group A Leading Specialty Insurance & Reinsurance Platform December 2025 Forward Looking Statements Statements made in this presentation that are not historical facts, including statements accompanied by words such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "likely," "may," "plan," "project," "realize," "should," "transform," "would," and other statements of similar expression and other words of similar expression, are forward-looking statements within the ...

Financial Performance Highlights - Birkenstock's FY25 revenue reached €2097 million, a 16% increase or 18% at constant currency[14,57] - Direct-to-Consumer (DTC) revenue was €795 million, up 11% or 12% at constant currency[14,57] - Business-to-Business (B2B) revenue grew by 20% or 21% at constant currency, reaching €1298 million[14,57] - Adjusted EBITDA increased by 20% to €667 million, with a margin of 318%, a 100 basis points increase[14,60] - Adjusted net profit rose by 44% to €346 million[14,62] - Adjusted EPS increased by 45% to €185[14,34] Regional Performance - Americas revenue reached €1086 million, up 15% or 18% at constant currency[17,57] - EMEA revenue was €785 million, a 14% increase at both reported and constant currency[17,57] - APAC revenue increased by 31% or 34% at constant currency, reaching €222 million[17,57] Financial Health - Net leverage decreased by 17% to 15x LTM Adjusted EBITDA[14,41] - Gross profit reached €1240 million with a margin of 591%, a 30 basis points increase[14,24] Outlook for FY26 - The company projects revenue to increase by 13-15% at constant currencies, targeting €2300-€2350 million[49,51] - Adjusted EBITDA is expected to be at least €700 million, with a margin of 300-305%[49,51]

Financial Performance - Total revenues reached $18.7 billion, a 5% increase in local currency[2] - Adjusted earnings per share increased by 10% to $3.94, excluding a $0.40 per share business optimization impact[3] - Adjusted operating margin increased by 30 bps to 17.0%, excluding a 170 bps business optimization impact[4] - Free cash flow was $1.5 billion[5] Revenue Breakdown - Consulting revenues were $9.4 billion, a 3% increase in local currency[3] - Managed Services revenues were $9.3 billion, a 7% increase in local currency[3] - Americas revenues were $9.1 billion, a 4% increase in local currency[2] - EMEA revenues were $6.9 billion, a 4% increase in local currency[2] - Asia Pacific revenues were $2.7 billion, a 9% increase in local currency[2] - Communications, Media & Technology revenues were $3.1 billion, an 8% increase in local currency[2] - Financial Services revenues were $3.6 billion, a 12% increase in local currency[2] Cash Return and Bookings - $1 billion was paid in dividends and $2.3 billion in share repurchases[5] - New bookings totaled $20.9 billion, reflecting 10% local currency growth, with a book-to-bill ratio of 1.1[5] AI and Ecosystem - Advanced AI bookings were $2.2 billion, with revenues of $1.1 billion, representing YoY growth of 76% and 120% respectively in USD[22] - Over 60% of revenue was driven by the top 10 ecosystem partners in Q1 FY26[11] Fiscal Year 2026 Outlook - Revenue growth in local currency is projected to be between 2% and 5%[8] - Adjusted earnings per share are expected to increase by 5% to 8% over FY25, reaching $13.52 - $13.90[8] - Free cash flow is projected to be between $9.8 billion and $10.5 billion[8] - At least $9.3 billion of cash is expected to be returned to shareholders, a 12% or $1 billion increase over FY25[29]

Investor Presentation NOVEMBER 2025 Forward-Looking Statements Historical financial and operating data in this presentation reflect the consolidated results of WD-40 Company and its subsidiaries (collectively, the "Company"). The Company markets maintenance products ("MP") under the WD-40®, 3-IN-ONE® and GT85® brand names. The WD-40 brand portfolio also includes the WD-40® Multi-Use Product, the WD-40 Specialist® and WD-40 BIKE® product lines. The Company markets the homecare and cleaning products ("HCCP") ...